糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Provention Bio从强生引进两个免疫疾病治疗化合物

2017-09-22 佚名 新浪医药新闻

ProventionBio强生免疫疾病
关注

9月21日，成立于2016年的美国生物制药公司Provention Bio与强生旗下的两家子公司Janssen Pharmaceutica NV 和 Janssen Sciences Ireland UC就两个用于免疫介导疾病治疗的候选药物签署了项目引进协议。


9月21日，成立于2016年的美国生物制药公司Provention Bio与强生旗下的两家子公司Janssen Pharmaceutica NV 和 Janssen Sciences Ireland UC就两个用于免疫介导疾病治疗的候选药物签署了项目引进协议。

第一个从强生公司引进的项目为PRV-6527，是一款口服的小分子集落刺激因子1受体（CSF-1R）抑制剂，Provention Bio计划将该化合物推进至用于克劳恩病治疗的概念验证性临床2a期研究，患者入组时间预计在明年上半年开始。

Provention Bio 科学创始人Francisco Leon 表示：“CSF-1R通路在克劳恩患者的肠道组织中存在过表达现象，未公开的研究数据显示PRV-6527对克劳恩病小鼠模型具有较好的治疗潜力。概念性验证临床2a期研究的目的是在患有中重度克劳恩病且对传统疗法响应不佳的患者中进行疗效验证。值得说明的是，目前还没有获得批准的用于中重度克劳恩病治疗的口服用药物。”

另一个引进项目则是PRV-300，是一款抗Toll样受体3（TLR3）单克隆抗体药物。Provention Bio计划在临床I/II期试验中对该药物用于中重度溃疡性结肠炎的治疗进行机理验证及概念验证性研究。公司同样计划在2018年上半年开始该研究的临床入组工作，PRV-300其它可治疗的适应症还包括严重流感和新兴病毒性疾病。

公司首席医学官及首席运营官Eleanor Ramos表示：“我们已经明确PRV-300对病毒感染及炎性疾病动物模型的抑制潜力。虽然我们首先开展的将会是用于中重度溃疡性肠炎治疗的机理验证性研究，但是我们同样打算进行适应症的探索，包括用于院内重症流感和新兴病毒感染的治疗研究。”

2017年4月，Provention Bio获得了2840万美元的融资，强生也参与其中。

Endpoints作者John Carroll评论道：“Provention Bio公司有三位关键领导人：首席执行官Ashleigh Palmer、首席医学官Eleanor Ramos和科学联合创始人Francisco Leon。Palmer 和 Leon曾创建专注于乳糜泻病治疗的Celimmune公司，药物是从安进公司引进的。Leon则是强生制药的前研发人员，对这两款引进的药物更是非常熟悉。”

PRV-6527还可能被进行治疗肠易激综合征（IBD）的疗效评估。Provention Bio之前引进了肠道病毒疫苗平台，意在预防或推迟由于注射柯萨奇病毒疫苗导致的1型糖尿病的发病风险。柯萨奇病毒感染被认为是导致全球一半以上1型糖尿病的致病原因。

Palmer表示：“从强生公司引进的PRV-6527 和 PRV-300将继续促进公司上个季度以来的良好发展势头，与我们关注免疫介导疾病的预防和治疗标的的战略相契合。同时，这两个交易也证明了Provention在转化医学方面的能力以及对于免疫介导疾病治疗具有良好研究和治疗特色的临床资产的把控能力。”

该项交易没有披露更多细节。今年4月份，Provention公布了公司的首个融资事件，并传言在2018年会有IPO的计划，Palmer透漏公司会继续专注于已有的3个资产，并会在项目得到积极试验数据后再考虑继续融资与否。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-08-19 sunylz

    #Bio#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-11-29 qindq

    #疾病治疗#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-03-22 longerg

    #Provention#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2018-09-04 wangyang7958

    #化合物#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 liuyong2980

    #强生#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 晓辰

    #免疫疾病#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1917667, encodeId=8b30191e6679f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 19 19:39:00 CST 2018, time=2018-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982776, encodeId=eb891982e762c, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Nov 29 21:39:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791804, encodeId=dacc1e9180445, content=<a href='/topic/show?id=f04314e7408' target=_blank style='color:#2F92EE;'>#Provention#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14774, encryptionId=f04314e7408, topicName=Provention)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f8f432, createdName=longerg, createdTime=Thu Mar 22 06:39:00 CST 2018, time=2018-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906366, encodeId=f4f8190636692, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Tue Sep 04 19:39:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271667, encodeId=847b12e166719, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50175, encryptionId=2c6c501e578, topicName=强生)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511241, encodeId=8d3c15112415b, content=<a href='/topic/show?id=3f922910088' target=_blank style='color:#2F92EE;'>#免疫疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29100, encryptionId=3f922910088, topicName=免疫疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a3610309283, createdName=晓辰, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601925, encodeId=9f3f16019251d, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun Sep 24 09:39:00 CST 2017, time=2017-09-24, status=1, ipAttribution=)]
    2017-09-24 sunylz

    #PRO#

    0